Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Published on 2019-10-24T13:55:41Z (GMT) by
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Cite this collection

Cai, Wen; Cai, Biao; Zhou, Juan; Chen, Yonghui; Zhang, Jin; Huang, Yiran; et al. (2019): Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.4711409.v1